目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T4472 | PARP | ||
NMS-P118是可口服的高选择性PARP-1抑制剂,用于癌症治疗,在HeLa 细胞中的IC50值为0.04 μM。 | |||
T3649 | PARP | ||
BGP-15 (BGP-15 2HCl) 是一种PARP 抑制剂,IC50和Ki 值分别为 120 和 57 μM,在缺血再灌注损伤后具有保护作用。 | |||
T7896 | PARP | ||
BYK204165 (RT-017290) 是一种选择性PARP1抑制剂,对重组人 PARP1的pIC50值为 7.35,pKi 值为7.05。它对鼠 PARP-2的pIC50值为 5.38 ,其对 PARP1 的选择性比对 PARP2 高 100 倍。 | |||
T22414 | PARP | ||
RBN012759 是选择性和具有口服活性的 PARP14抑制剂,IC50值小于3 nM,可降低促肿瘤巨噬细胞功能并在肿瘤外植体中引发炎症反应,比对 monoPARPs 的选择性高 300 倍,比对 polyPARPs 的选择性高 1000 倍。 | |||
T13795 | Sirtuin | ||
Nicotinamide riboside 是维生素 B3 的来源,可以增强氧化代谢并防止高脂肪饮食诱导的代谢异常。它是具有口服活性的 NAD+的前体,增加 NAD+水平并激活SIRT1和SIRT3,可用于研究阿尔茨海默氏病的认知退化。 | |||
T7443 | PARP PPAR | ||
4'-Methoxychalcone 通过PPARγ活化调节脂肪细胞分化,并调节参与胰岛素敏感性的脂肪组织中各种脂肪因子的表达和分泌,具抗肿瘤和抗炎活性。 | |||
T9593 | PARP | ||
Senaparib (IMP4297) 是一种选择性和口服有效的PARP1/2抑制剂,具有强效的抗肿瘤活性。 | |||
T22749 | PARP | ||
DR2313 是一种选择性,竞争性的和可透过血脑屏障的PARP 抑制剂,对PARP-1和PARP-2的IC50值分别为 0.20 和 0.24 μM。它在体内外均有对缺血性损伤的神经保护作用。 | |||
T9430 | PARP | ||
Venadaparib (NOV140101) 是一种选择性和具有口服活性的 PARP 抑制剂,对 PARP1和 PARP2的 IC50分别为 1.4 和 1.0 nM。它可防止 DNA 单链断裂 (SSB) 的修复,可研究实体瘤。 | |||
T8150 | PARP Endogenous Metabolite | ||
Nudifloramide (1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxamide) 是烟酰胺-腺嘌呤二核苷酸(NAD) 降解的一种最终产物,可显著抑制PARP-1活性。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01188 | PARP Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells | ||
Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 2-3 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrated to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors are thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-02465 | PARP Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells | ||
Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 2-3 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrated to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors are thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPH-01943 | PARP4 Protein, Human, Recombinant (His) | Human | E. coli | ||
PARP4 Protein, Human, Recombinant (His) is expressed in E. coli.
|
|||||
TMPH-01879 | PARP11 Protein, Human, Recombinant (His) | Human | E. coli | ||
Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins. Plays a role in nuclear envelope stability and nuclear remodeling during spermiogenesis.
|
|||||
TMPH-01882 | PARP9 Protein, Human, Recombinant (His) | Human | E. coli | ||
ADP-ribosyltransferase which, in association with E3 ligase DTX3L, plays a role in DNA damage repair and in immune responses including interferon-mediated antiviral defenses. Within the complex, enhances DTX3L E3 ligase activity which is further enhanced by PARP9 binding to poly(ADP-ribose). In association with DTX3L and in presence of E1 and E2 enzymes, mediates NAD(+)-dependent mono-ADP-ribosylation of ubiquitin which prevents ubiquitin conjugation to substrates such as histones. During DNA repair, PARP1 recruits PARP9/BAL1-DTX3L complex to DNA damage sites via PARP9 binding to ribosylated PARP1. Subsequent PARP1-dependent PARP9/BAL1-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites. In response to DNA damage, PARP9-DTX3L complex is required for efficient non-homologous end joining (NHEJ); the complex function is negatively modulated by PARP9 activity. Dispensable for B-cell receptor (BCR) assembly through V(D)J recombination and class switch recombination (CSR). In macrophages, positively regulates pro-inflammatory cytokines production in response to IFNG stimulation by suppressing PARP14-mediated STAT1 ADP-ribosylation and thus promoting STAT1 phosphorylation. Also suppresses PARP14-mediated STAT6 ADP-ribosylation.
|
|||||
TMPH-01880 | PARP2 Protein, Human, Recombinant (His) | Human | E. coli | ||
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage. Mediates glutamate and aspartate ADP-ribosylation of target proteins in absence of HPF1. Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 conferring serine specificity by completing the PARP2 active site. PARP2 initiates the repair of double-strand DNA breaks: recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones, thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks. In addition to proteins, also able to ADP-ribosylate DNA: preferentially acts on 5'-terminal phosphates at DNA strand breaks termini in nicked duplex.
|
|||||
TMPY-02421 | PARP3 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
Poly(ADP-ribose) polymerase 3 (PARP3) is an important member of the PARP family and shares high structural similarities with both PARP1 and PARP2. Poly(ADP-ribose) polymerase 3 (PARP3), a critical player in cellular response to DNA double-strand breaks (DSBs), plays an essential role in the maintenance of genome integrity. The ADP ribosyl transferase [poly(ADP-ribose) polymerase] ARTD3(PARP3) is a newly characterized member of the ARTD(PARP) family that catalyzes the reaction of ADP ribosylation, a key posttranslational modification of proteins involved in different signaling pathways from DNA damage to energy metabolism and organismal memory.
|
|||||
TMPH-01941 | PARP12 Protein, Human, Recombinant (His & Myc) | Human | E. coli | ||
PARP12 Protein, Human, Recombinant (His & Myc) is expressed in E. coli.
|
|||||
TMPH-01942 | PARP14 Protein, Human, Recombinant (His & Myc) | Human | HEK293 | ||
PARP14 Protein, Human, Recombinant (His & Myc) is expressed in HEK293.
|
|||||
TMPH-01944 | PARP9 Protein, Human, Recombinant (His & Myc) | Human | HEK293 | ||
PARP9 Protein, Human, Recombinant (His & Myc) is expressed in HEK293.
|
|||||
TMPH-01881 | PARP2 Protein, Human, Recombinant (GST & His) | Human | Baculovirus | ||
PARP2 Protein, Human, Recombinant (GST & His) is expressed in Baculovirus with N-terminal GST tag and C-terminal 6xHis tag. The predicted molecular weight is 92.8 kDa. Accession number: Q9UGN5
|
|||||
TMPH-01056 | Caspase-3 Protein, Human, Recombinant (His) | Human | E. coli | ||
Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage. Cleaves and inhibits serine/threonine-protein kinase AKT1 in response to oxidative stress. Cleaves XRCC4 and phospholipid scramblase proteins XKR4, XKR8 and XKR9, leading to promote phosphatidylserine exposure on apoptotic cell surface.
|
|||||
TMPY-02831 | Caspase-7 Protein, Human, Recombinant (His) | Human | E. coli | ||
Caspase 7, also known as caspase-7 and MCH3, belongs to the cysteine-aspartic acid protease (caspase) family. Caspases play a role in the signal transduction pathways of apoptosis, necrosis and inflammation. There are two major classes of caspases: initiators and effectors. The initiator isoforms (caspases-1,-4,-5,-8,-9,-10,-11,-12) are activated by, and interact with, upstream adaptor molecules through protein-protein interaction domains known as CARD and DED. Effector caspases (-3,-6,-7) are responsible for cleaving downstream substrates and are sometimes referred to as the executioner caspases. Caspase 7 exists in lung, skeletal muscle, liver, kidney, spleen, heart, and moderately in testis. Caspase 7 cannot be detected in the brain. Caspase 7 functions in the activation cascade of caspases responsible for apoptosis execution. It cleaves and activates sterol regulatory element binding proteins (SREBPs). It proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp- -Gly-217' bond. Overexpression promotes programmed cell death.
|